Noctofer (Lormetazepam)

Lormetazepam, the active ingredient in Noctofer, is a benzodiazepine presented as an oral tablet for oral use. It acts as a hypnotic and sedative and is indicated for the short‑term treatment of insomnia in adult patients. It is marketed within the European Union and conforms to EU regulatory standards.

GNH USA supplies Noctofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows Good Distribution Practice, ensures product integrity, and provides reliable logistics to healthcare providers across multiple continents.

Lormetazepam is a benzodiazepine hypnotic used primarily in disorders of sleep initiation and maintenance.

Insomnia (sleep initiation difficulty): helps patients fall asleep faster during short‑term therapy. Sleep maintenance insomnia: reduces nighttime awakenings to improve sleep continuity. Transient anxiety‑related insomnia: alleviates sleep disturbance associated with brief anxiety episodes. Adjustment disorder with insomnia: provides temporary relief of sleep disruption during stressful periods. Pre‑operative anxiety: offers short‑acting sedation to facilitate sleep before minor procedures.

Lormetazepam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness - Dizziness - Headache - Memory impairment

Serious or Rare Side Effects: - Respiratory depression - Dependence or withdrawal syndrome - Severe allergic reactions (e.g., rash, angioedema)

When prescribing Lormetazepam, clinicians should consider several safety measures. - Dosage adjustment: use the lowest effective dose, especially in elderly patients. - Duration of therapy: limit to short‑term (typically ≤2–4 weeks) to avoid dependence. - Renal/hepatic impairment: consider dose reduction and monitor plasma levels. - Concomitant CNS depressants: avoid or monitor for additive sedation. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lormetazepam can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: increased risk of respiratory depression. - Other benzodiazepines: cumulative sedation and overdose potential.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): may increase sedation. - Antihistamines: may enhance drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations of lormetazepam.